company background image
ATOR

Alligator Bioscience OM:ATORX Stock Report

Last Price

kr1.44

Market Cap

kr313.2m

7D

7.2%

1Y

-57.8%

Updated

05 Oct, 2022

Data

Company Financials +
ATORX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ATORX Stock Overview

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden.

Alligator Bioscience AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alligator Bioscience
Historical stock prices
Current Share Pricekr1.44
52 Week Highkr3.59
52 Week Lowkr1.30
Beta0.98
1 Month Change-19.05%
3 Month Change-4.65%
1 Year Change-57.77%
3 Year Change-88.21%
5 Year Change-95.01%
Change since IPO-96.23%

Recent News & Updates

Jul 30
Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

ATORXSE BiotechsSE Market
7D7.2%17.0%5.1%
1Y-57.8%-28.8%-24.4%

Return vs Industry: ATORX underperformed the Swedish Biotechs industry which returned -28.8% over the past year.

Return vs Market: ATORX underperformed the Swedish Market which returned -24.4% over the past year.

Price Volatility

Is ATORX's price volatile compared to industry and market?
ATORX volatility
ATORX Average Weekly Movement7.3%
Biotechs Industry Average Movement8.5%
Market Average Movement7.0%
10% most volatile stocks in SE Market11.5%
10% least volatile stocks in SE Market4.3%

Stable Share Price: ATORX is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ATORX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200049Søren Bregenholthttps://www.alligatorbioscience.se

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells.

Alligator Bioscience AB (publ) Fundamentals Summary

How do Alligator Bioscience's earnings and revenue compare to its market cap?
ATORX fundamental statistics
Market Capkr313.23m
Earnings (TTM)-kr162.82m
Revenue (TTM)kr19.64m

16.1x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATORX income statement (TTM)
Revenuekr19.64m
Cost of Revenuekr110.25m
Gross Profit-kr90.61m
Other Expenseskr72.21m
Earnings-kr162.82m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 20, 2022

Earnings per share (EPS)-0.74
Gross Margin-461.25%
Net Profit Margin-828.86%
Debt/Equity Ratio0%

How did ATORX perform over the long term?

See historical performance and comparison